The Enterey Blog

Facebook and the Pharma Industry

Posted by Tita Tavares on Thu, May 26, 2011 @ 03:17 PM

 Purple Social Media Enterey Blog6 resized 600

Is Social Media
that Important to Pharma Companies?

 

As a follow up to our May 5, 2011 post, Pharma, Social Media and the FDA's Delay, here's an interesting development that just might help push pharma companies to stay on top of the FDA to issue further guidelines on the industry's interaction in the social media world.

By August 15th, Facebook will require pharmaceutical companies to enable and allow public comments on their posts. This could be a huge risk and may be a big problem for pharma marketers, posing whether or not the benefits of Facebook are worth the effort.

Basically, it will take a lot of monitoring to make sure the conversations and dialogues on their company pages remain in a positive light for the manufacturers. Will this solution be cost prohibiting or will it be minor when weighed against the benefits and attraction Facebook interaction creates?

Is this decision made by Facebook a good one or not? This type of action may be what the social media mogul needed to keep their brand and product consistent all the way through. Facebook is created to be a virtul forum for real conversations to take place. It allows people to interact in the comforts of their own environments. Taking away the ability to engage in a virtual dialogue would be like telling someone, "Let's talk but do not say anything. I am the only one allowed to talk here but please listen." That isn't much of a conversation anyone would want to engage in, virtual or not!

Though Facebook's policies may be a hurdle for pharma companies and their marketing teams--if they play it right--they should be able to leap easily over the challenges and continue to use the virtual platform as a vehicle to set a casual tone in relating to their customers and patients. The informal approach could lead to patients feeling like they really matter to these seemingly HUMONGEOUS companies and at that, patient loyalty would be well worth the effort.

Read Article   

From stacyrobin on twitter: New realities for pharma? RT @kbkcomm: Hmmm...@Facebook says: pharmas must enable comments by August 15 http://ht.ly/52X6q (http://twitter.com/stacyrobin/statuses/73827493462806529

To get a better understanding of Facebook’s policies towards the pharma industry, read Intouch Solution’s Blog for their view and comments.

Published by: Tita Tavares, Enterey | Director, Brand Development


Stay Current! Stay connected to Enterey

twitter | facebook | linkedin 

Next week’s blog:
Facility Start Up in Biotech

Resource link:
http://bit.ly/gd70PZ

ambro


 

Tags: FDA, Life Sciences Industry News, FDA guidelines, Social Media, Communication, Social Media and Pharma, Facebook, Risks, Life Sciences Communication, Pharma Marketing

Pharma, Social Media and the FDA's Delay

Posted by Tita Tavares on Thu, May 05, 2011 @ 12:40 PM

Is Pharma at a HALT with Blogging, Sharing, Posting and Tweeting Because of the FDA’s Delay of Its Social Media Guidance?

Enterey FDA and Social Media


We’re into the second quarter of 2011 and the hotly-anticipated guidance document has yet to be seen. What should the industry be expecting?

From what I can tell after checking our company’s Enterey Twitter page, Pharma social media is alive and well but under what direction are they communicating with the online community? Are they putting themselves at risk or is there opportunity that the FDA is holding them back from by delaying this process?

The FDA had been expected to issue a draft of guidelines in the first quarter of this year, but the deadline has gone and went. The purpose of these guidelines is to give the Life Sciences industries direction on how they interact and communicate through social media platforms with physicians, allied healthcare professionals and consumers due to the immense amount of information available and the potential threats that arise from this very informal line of communication.

In the Consensus Interactive presentation given back at the FDA Part 15 Public Hearing on November 15, 2009, it’s stated that the Pharma industry is at a crossroads with the modern development of Social Media. The FDA needs to act now in support of the industry taking advantage of the growth benefits and tremendous opportunities that just may be passing them by. It’s been almost two years later since the hearing.

Rohit Bhargave of 360 Digital Influence, gives a well-dressed commentary on what we can expect from the US regulator in regards to this ever changing challenge of social media and affects on the world of Pharma. For further details, read his explanation to see how this might just change your future blogging, sharing, posting and tweeting.

Published by: Tita Tavares, Enterey | Director, Brand Development
 

Stay Current! Stay connected to Enterey
twitter | facebook | linkedin 

Next week’s blog:
Facility Start up in Biotech

Resource link:
http://bit.ly/gd70PZ
jscreationzs / FreeDigitalPhotos.net

Tags: FDA, Life Sciences News & Hot Topics, Social Media, Interactive, Communication, Pharma